Cancer Care

 

 
A Prospective Study of Partial Breast Adjuvant Radiation Therapy After Resection of Borderline and Malignant Phyllodes Tumors
Principal Investigator (?)
Study Number
D0929
Summary
In 2008 a research study conducted by Dr. Barth involving 46 women determined that whole
breast radiation therapy performed after a lumpectomy of borderline and malignant phyllodes
tumors decreases rate of recurrence. None of the 46 participants developed a local
recurrence.

Based on information we have learned from research studies, we recommend whole breast
radiation therapy for women with malignant and borderline phyllodes tumors after they
receive a lumpectomy.

New methods for delivering breast radiotherapy are being developed that allow radiation to
be delivered solely to the site of the surgical resection. This is called partial breast
radiation. The main advantage of partial breast radiation is that it simplifies treatment
for the patient. Radiation is delivered twice a day for 5 days, rather than 5 days per week
for 6 weeks. The main concern is that partial breast radiation might miss other sites of
breast cancer in the breast receiving the radiation.

Evidence is accumulating from research studies that partial breast radiation therapy after
surgical removal of the more common type of breast cancer, invasive ductal carcinoma, the
breast results in rates of local recurrence that are comparable to those seen after whole
breast radiation therapy.

In contrast to patients with invasive ductal cancers of the breast, it is very rare for
patients to have phyllodes tumors that appear in more than one area of the breast. Review of
research data determined that cancer recurrences seen in patients with phyllodes tumors that
had undergone lumpectomies were almost always at the original tumor site. Therefore, partial
breast radiation is likely to be as effective as whole breast radiation therapy after
resection of malignant phyllodes tumors.

The purpose of the study is to determine what the chances are that a phyllodes tumor will
recur in the breast when the breast is treated with partial breast radiation therapy after a
lumpectomy.
Phase (?)
Phase II
Sponsor (?)
Available at the following location(s)

Lebanon

View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.